CN101781358A - Novel antibacterial peptide and preparation method and application thereof - Google Patents
Novel antibacterial peptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN101781358A CN101781358A CN200910223409A CN200910223409A CN101781358A CN 101781358 A CN101781358 A CN 101781358A CN 200910223409 A CN200910223409 A CN 200910223409A CN 200910223409 A CN200910223409 A CN 200910223409A CN 101781358 A CN101781358 A CN 101781358A
- Authority
- CN
- China
- Prior art keywords
- lys
- arg
- ala
- gly
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 4
- 241000192125 Firmicutes Species 0.000 claims abstract 2
- 206010017533 Fungal infection Diseases 0.000 claims abstract 2
- 208000031888 Mycoses Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims abstract 2
- 208000027136 gram-positive bacterial infections Diseases 0.000 claims abstract 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 14
- 230000002147 killing effect Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 23
- 230000000855 fungicidal effect Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102220369446 c.1274G>A Human genes 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000002949 hemolytic effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 108010026389 Gramicidin Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108010059993 Vancomycin Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000010079 rubber tapping Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 6
- 229960003165 vancomycin Drugs 0.000 description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- NFEQUGKCQWAGLY-UAAVROCESA-N parasin i Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CCCCN NFEQUGKCQWAGLY-UAAVROCESA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 241001233037 catfish Species 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 108010049120 parasin I Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 101150112970 up gene Proteins 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220369447 c.1352G>A Human genes 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- -1 methoxycarbonyl (Fmoc) Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一组新的抗菌肽，这些抗菌肽具有比天然抗菌肽更强的杀菌活性，对各种致病菌的杀灭效果都很好。本发明还公开了该组抗菌肽的制备方法，可以用固相化学法合成，也可以通过基因工程表达获得。本发明合成抗菌肽可以用于制备治疗革兰氏阳性菌、革兰氏阴性菌或真菌感染引起的疾病的药物。The invention provides a group of novel antibacterial peptides, which have stronger bactericidal activity than natural antibacterial peptides, and have good killing effects on various pathogenic bacteria. The invention also discloses the preparation method of the group of antibacterial peptides, which can be synthesized by solid-phase chemical method, and can also be obtained by gene engineering expression. The synthetic antibacterial peptide of the invention can be used to prepare medicines for treating diseases caused by Gram-positive bacteria, Gram-negative bacteria or fungal infections.
Description
The application is that application number is 200410068195.X, the applying date to be dividing an application of November 16, denomination of invention in 2004 original application that is one group of new antibacterial peptide and its production and application.
Technical field
The present invention relates to one group of antibacterial peptide, its preparation method and the application in preparation treatment bacterium, fungi, medicine for treating viral infections.
Background technology
Antibacterial peptide is the micromolecule polypeptide of a kind of biologically active of organism through inducing generation, generally is made up of 20-60 amino acid, and molecular weight is about 2000-7000D.Along with Medical Immunology and molecular biological developing rapidly, the research of antibacterial peptide more and more becomes the heat subject in biotechnology and the biomedicine field.Up to now, found to surpass more than 200 kind of antibacterial peptide on many animals (especially insect), plant, microorganism and human body, this class small peptide not only has the germicidal action of wide spectrum to bacterium, fungi, and virus, protozoon and cancer cells are also had attack function.Clinical trial also shows, maybe may cause under the situation of courses of infection the organism infection germ, and antibiotic Toplink is killed the germ of having invaded fast, and can stop germ continue infect.
Along with to the deepening continuously of antibacterial peptide primary structure and higher structure research, existing many investigators study the 26S Proteasome Structure and Function of these antibacterial peptides, find that alpha-helix degree and its fungicidal activity in the molecule are closely related under the hydrophobic environment of analogue membrane.Result of study shows that antibacterial peptide is to make bacterial cell membrane seepage and killing bacteria (Nakajima Y.etal., J.Biol.Chem, 262:1665-1669 by the integrity of destroying film in addition; ZasloffM.Nature, 2002,415:389-395).Therefore there is the people to attempt by α-Luo Xuanjiegou in the increase molecule or improve in the polypeptide to contain polypeptide (the Broth W.B.etal. that the amino acid whose ratio of positive charge is sought stronger anti-microbial activity, Antimicrobial Agents Chemotherapy, 2001,45:1894-1895; HongS.Y.etal., Peptides, 2001,22:1669-1674).
United States Patent (USP) 6,316,594 disclose natural antibacterial peptide parasinI, it is a kind of new separating from catfish, be to be that its epithelium mucous layer of invasion that prevents microorganism produces a kind of polypeptide with very strong anti-microbial effect by catfish when the epidermis injury, belong to the alpha-helix antibacterial peptide, molecular weight is 2000.4Da, be made up of 19 amino-acid residues, sequence is: Lys Gly Arg Gly Lys Gln Gly Gly Lys Val Arg Ala Lys Ala Lys Thr Arg Ser Ser.Although the Parasin I in the patent documentation shows very effective broad spectrum antibiotic activity to microorganism, comprise gram-positive and gram-negative bacteria and fungi, and without any hemolytic.Its synthetic derivative also has effective activity.But find that but its fungicidal activity is lower in our experiment, native sequences is difficult to be applied to clinical, but Parasin I does not have hemolytic substantially, and it is less that the sequence transformation that it some are relevant and the exploitation of function application facet are also carried out.
So the present invention wants by the transformation to Parasin I sequence, obtains the stronger antibacterial peptide that has medicinal exploitation to be worth of fungicidal activity, promptly can form new patented technology.
Summary of the invention
One of technical issues that need to address of the present invention provide one group of antibacterial peptide.
Two of the technical issues that need to address of the present invention provide the preparation method of one group of antibacterial peptide.
Three of the technical issues that need to address of the present invention are the application that disclose described antibacterial peptide.
Inventive concept of the present invention is such: we are through after finding to insert at interval hydrophobic amino acid and positively charged amino acid after the test of many times in Parasin I sequence, form two hydrophobic amino acids and two sequences that positive charge amino acid is alternately arranged, such structure reduced toxicity also improves fungicidal activity.Screen following 12 sequences after transforming, pressing down bactericidal assay proves that its fungicidal activity is greatly improved.And hemolytic toxicity does not have to change substantially, is hopeful very much to be used for the treatment of the exploitation of the new drug of infectation of bacteria.
Antibacterial peptide provided by the invention is to design synthetic on to the sequence of natural antibacterial peptide, basis of structural analysis, and a series of sequences of they this are named as GKV, and sequence is as follows:
GKV-1：Lys?Gly?Ala?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Val?Ala?Arg?Lys?Ala?Leu?Lys?Arg
Ala?Gly?Lys
GKV-2：Lys?Gly?Gly?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
Arg?Ala?Gly?Arg
GKV-3：Lys?Gly?Gly?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
GKV-4：Lys?Gly?Val?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Cys?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
GKV-5：Lys?Gly?Ala?Arg?Arg?Gly?Ala?Lys?Arg?Gly?Gly?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
GKV-6：Lys?Gly?Ala?Arg?Arg?Leu?Ala?Lys?Arg?Ser?Gly?Lys?Lys?Val?Ala?Arg?Lys?Ala?Gly?Arg
GKV-7：Lys?Phe?Ala?Arg?Arg?Leu?Ala?Lys?Arg?Leu?Gly?Lys?Lys?Val?Ala?Arg?Lys?Leu?Gly?Arg
GKV-8：Lys?Phe?Leu?Arg?Arg?Leu?Ile?Lys?Arg?Leu?Val?Lys?Lys?Val?Leu?Arg?Lys?Leu?Gly?Arg
GKV-9：Lys?Ala?Ala?Lys?Lys?Ala?Ala?Lys?Arg?Ala?Ala?Lys?Lys?Ala?Thr?Arg
GKV-10：Lys?Ala?Leu?Lys?Lys?Ala?Leu?Lys?Arg?Ala?Leu?Lys?Lys?Ala?Leu?Arg
GKV-11：Lys?Gly?Leu?Lys?Lys?Gly?Leu?Lys?Arg?Gly?Leu?Lys?Lys?Gly?Leu?Arg
GKV-12：Lys?Ala?Thr?Lys?Lys?Ala?Leu?Lys?Arg?Ala?Gly?Lys?Lys?Ala?Thr?Arg
One group of antibacterial peptide provided by the invention, its preparation method can be a mechanochemical method, also the encoding gene of antibacterial peptide can be cloned on the carrier, expresses the back then and obtain in host cell.Wherein expression vector can be a kind of in plasmid or the virus; host cell can be a prokaryotic cell prokaryocyte; comprise intestinal bacteria, subtilis etc., host cell can be eukaryotic cell also, comprise yeast cell, vegetable cell, insect cell and mammalian cell etc.The antibacterial peptide of preparation can be identified by mass spectrum.
In order to further investigate the structure-function relationship of this quasi-biology active antibacterial peptide of the present invention, the Pioneer Peptide synthesizer that utilizes U.S. application system biotech firm to produce prepares one group of antibacterial peptide disclosed by the invention and antibacterial peptide in contrast, to study.
Utilize 96 well plate method to detect fungicidal activity (the In Yup Park etc of polypeptide; FEBS Letters; 437 (1998) 258-262) with synthetic natural antibacterial peptide GramicidinS in advance, parasinI, magaininII is contrast, carries out fungicidal activity and detects.The result shows that the fungicidal activity of antibacterial peptide of the present invention is better than the fungicidal activity of described three kinds of natural antibacterial peptides.
Antibacterial peptide also might act on high organism and comprise human body cell in efficient sterilizing, because the mode of action of antibacterial peptide all is that perforation makes the death of cell generation seepage on cytolemma.So can make red corpuscle generation seepage as its virose standard whether antibacterial peptide, if antibiotic Toplink makes the oxyphorase generation seepage in the red corpuscle, just can be by detecting OD
490Value is determined toxic size.Therefore the present invention has also detected the hemolytic activity of antibacterial peptide to human erythrocyte, and experiment shows that antibacterial peptide hemolysis rate value is very low, confirms that the hemolytic toxicity of antibacterial peptide of the present invention is minimum.
In addition, again antibacterial peptide of the present invention is carried out acute toxicity test in the animal body, prove the antibacterial peptide free of toxic effects.Carry out the test of antibacterial peptide again, show that antibacterial peptide has significant inhibitory effect to infection of staphylococcus aureus small white mouse acute infection aureus with inhibition.
The invention provides one group of new artificial design synthetic antibacterial peptide.Can adopt mechanochemical method preparation easily or with the gene clone of encoding antimicrobial peptide to carrier, enter then and express the back in the host cell and obtain.This antibacterial peptide has the wide spectrum killing activity to Gram-negative bacteria, gram-positive microorganism, fungi, virus, and than natural antibacterial peptide stronger fungicidal activity is arranged, but the animal and plant cell is not had any toxic action.And the mouse test of streptococcus aureus acute infection fungicidal activity is shown that antibacterial peptide gives 0.25mg/kg dosage by antibacterial peptide, just can reach 100% sterilization inhibiting rate, just can reach 100% sterilization inhibiting rate and will give 4.0mg/kg dosage as the vancomycin of killing the streptococcus aureus specifics, show that antibacterial peptide of the present invention has very significant sterilization effect to the streptococcus aureus acute infection, so antibacterial peptide of the present invention can be applicable to prepare the medicine of the disease that treatment gram-positive microorganism, Gram-negative bacteria or fungi infestation causes.
Description of drawings
Fig. 1 is the mass spectrum of antibacterial peptide GKV-4.
Embodiment
Synthetic preparation of the solid state chemistry of embodiment 1 antibacterial peptide and separation and purification
Prepare GKV-1 to GKV-12 by above-mentioned sequence, prepare GramicidinS simultaneously, parasinI and magaininII are in contrast.
The sequence of GramicidinS:
Val?Orn?Leu?Phe?Pro?Val?Orn?Leu?Phe?Pro
The sequence of ParasinI
Lys?Gly?Arg?Gly?Lys?Gln?Gly?Gly?Lys?Val?Arg?Ala?Lys?Ala?Lys?Thr?Arg?Ser?Ser
The sequence of magaininII:
Gly?Ile?Gly?Lys?Phe?Leu?His?Ser?Ala?Lys?Lys?Phe?Gly?Lys?Ala?Phe?Val?Gly?Glu
Ile?Met?Asn?Ser
Present embodiment adopts mechanochemical method synthetic, the Pioneer Peptide synthesizer that used instrument is produced for u.s.a. applied biosystem company.The synthetic polypeptide is used reverse column purification after the TFA of excessive concentrations shears, the polypeptide behind the purifying is identified by mass spectrum.Concrete testing sequence is as follows:
1, the preparation of antibacterial peptide (GKV-1 with preparation 0.1mmol amount is an example)
Below all the preparation antibacterial peptides reagent all purchase in u.s.a. applied biosystem company.
The GKV-1 peptide sequence of preparation is
N-Lys?Gly?Val?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Cys?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys-C
Preparation holds the N end to carry out one by one from C, is controlled automatically by synthesizer.At first weighing 0.1mmol's combines the resin that first amino acid is Arg (purchasing in u.s.a. applied biosystem company); the dress post; use 20% piperidines dimethyl formamide solution deprotection again; dimethyl formamide cleans; the total free aminoacids of 9-tablet held before the breast by officials methoxycarbonyl (Fmoc) protection is dissolved in carbodiimide (DCC); hydroxybenzotriazole (HOBt)/diisopropyl ethyl amine (DIPEA); solution after the dissolving is post cocycle coupled reaction 30 minutes, dimethyl formamide clean repeat above deprotection to the coupled reaction step up to preparation end (the concrete operations step is seen pioneer Peptide synthesizer operational guidance).
Polypeptide after the preparation is sheared through following steps:
Take off reacted resin, add Type B and shear liquid (88% trifluoroacetic acid, 5% phenol, 5% water, 2% tri isopropyl silane), room temperature reaction 2 hours filters, the precooling anhydrous diethyl ether that adds 10 times of volumes in the filtrate, 4000 rev/mins centrifugal 10 minutes, collecting precipitation and drying at room temperature.
2, antibacterial peptide purifying
The a certain amount of dried polypeptide of weighing is dissolved in 0.1% trifluoroacetic acid, and sample preparation is after elution peak is collected in oppositely post separation (elutriant is 0.1% trifluoroacetic acid that contains 80% second cyanogen).
At first design the GKV-4 gene of composite coding antibacterial peptide, it is cloned into (available from Amersham Pharmcia Biotech company) on the pGEX-4T1 carrier, transformed into escherichia coli JM109 then, through IPTG abduction delivering GST-GKV-4 fusion rotein, after the zymoplasm cutting, get antibacterial peptide GKV-4 again.
The ATP that uses among the embodiment, IPTG, T
4Polynueleotide kinase, T
4Dna ligase, Klenow enzyme, restriction enzyme are BIOLAB company product except that specializing, it is that worker company product is given birth in Shanghai that test kit is reclaimed in rubber tapping, and oligonucleotide is that Shanghai Sangon Biological Engineering Technology And Service Co., Ltd is synthetic.Zymoplasm is sheared test kit and is purchased the company in SIGMA.
The separation of relative dna, purifying, pcr amplification, enzymolysis, plasmid transform host bacterium, fragment and reclaim, connect the equimolecular clone operations and all carry out according to " the molecular cloning experiment guide " that the husky nurse Brooker of J. etc. is write.E. coli jm109 is cultivated in the LB of liquid or solid substratum.
Adopt the dna sequence dna of the preferred antibacterial peptide GKV-4 gene of codon design coding of intestinal bacteria preference, sequence is as follows.5 ' end at antibacterial peptide GKV-4 gene is introduced restriction enzyme site BamHI (GGATCC), adds terminator codon (TAG) at 3 ' end, and the length that gained makes up gene is 72bp.
By directly synthetic this nucleotide fragment of dna synthesizer.At first gene is increased with PCR method.Design a pair of primer: 5 '-CCTAGGTTTCCACA-3 ' and 5 '-GATGAAGTTTCG-3 '.The PCR reaction conditions is as follows: 94 ℃, and 30 seconds; 45 ℃, 45 seconds; 72 ℃, 30 seconds; React 30 circulations.After the PCR reaction this segment being mended flat back through the Klenow enzyme cuts with the BamHI enzyme, enzyme section cracked ends is crossed rubber tapping recovery back (rubber tapping reclaimer operation reference reagent box operation instructions) and is connected back transformed into escherichia coli JM109 with the BamHI of pGEX-4T1 carrier and the double digestion segment of SmaI, and transformant is cut evaluation, screening by the SmaI enzyme.Transformant is through IPTG abduction delivering GST-GKV-4 fusion rotein.Fusion rotein with the GST affinity column purifying after obtain antibacterial peptide GK V-4, concrete operations reference reagent box operation instructions after the zymoplasm cutting.
The GKV-4 protein sequence:
Lys?Gly?Val?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Cys?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
The nucleotide sequence of coding GKV-4:
AAAGGTGTTCGTAAAGGGGCCAAACGCCAGGGTTGCAAGAAACTTGCCCGTAAGGCTTTGAAG
Embodiment 3 expression of antibacterial peptide GKV-4 gene in yeast cell
The ATP that uses in the present embodiment, IPTG, T
4Polynueleotide kinase, T
4Dna ligase, Klenow enzyme, restriction enzyme are BIOLAB company product except that specializing, it is that worker company product is given birth in Shanghai that test kit is reclaimed in rubber tapping, and oligonucleotide is that Shanghai Sangon Biological Engineering Technology And Service Co., Ltd is synthetic.Zymoplasm is sheared test kit and is purchased the company in SIGMA.
The GKV-4 gene of design composite coding antibacterial peptide, process BamHI enzyme is cut with the dna sequence dna of the GST that encodes and is connected, after be connected among the plasmid pBluescriptSKII (available from U.S. Stratagene company), transformed into escherichia coli DH5 α (available from DSMZ of Wuhan University), after the extraction plasmid proves that through order-checking sequence is correct, plasmid is through EcoRI, after cutting, the XhoI enzyme is connected in the pPIC9 carrier (available from American I nvitrogen company), the back transforms pichia yeast bacterial strain KM71 (available from American I nvitrogen company), methanol induction expressed fusion protein GST-GKV-4.
The separation of relative dna, purifying, pcr amplification, enzymolysis, plasmid transform host bacterium, fragment and reclaim, connect the equimolecular clone operations and all carry out according to " the molecular cloning experiment guide " that the husky nurse Brooker of J. etc. is write.Pichia yeast bacterial strain KM71 cultivates in the BMGY of liquid or solid substratum, and yeast strain is cultivated in the BMMY substratum during methanol induction expressed fusion protein GST-GKV-4, and adding methyl alcohol to final concentration every 24 hours is 1%.
Adopt the codon design preferred antibacterial peptide GKV-4 of coding of yeast preference and the dna sequence dna of GST.5 ' end at antibacterial peptide GKV-4 gene is introduced restriction enzyme site BamHI (GGATCC), add terminator codon (TAG) and EcoRI restriction enzyme site (GAATCC) at 3 ' end, the length that gained makes up gene is 78bp, connect the dna sequence dna of coding GST simultaneously at GKV-4 gene leading portion, the 5 ' end of while at the dna sequence dna of GST added an XhoI restriction enzyme site.
The preparation of GKV-4 nucleotide fragment: by the direct composite coding GKV-4 of dna synthesizer nucleotide fragment.With PCR method gene is increased then.Design a pair of primer 5 '-CCTAGGTTTCCACA-3 ' and 5 '-CTTAAGGATGAAGTTTCG-3 '.The PCR reaction conditions is as follows: 94 ℃, and 30 seconds; 45 ℃, 45 seconds; 72 ℃, 30 seconds; React 35 circulations.
The coding GST dna sequence dna preparation: design a pair of primer
5’-CTCGAGATGTCCCCTATACTAGGTT-3’
5’-CAGTGCTACGCCGGCGAG-3’
With above primer amplification pGEX-4T1 carrier.The PCR reaction conditions is as follows: 94 ℃, and 30 seconds; 45 ℃, 45 seconds; 72 ℃, 60 seconds; React 30 circulations.
Amplified fragments is connected with plasmid: the pcr amplification segment of GKV-4 is mended flat back through the Klenow enzyme cut with BamHI and EcoRI enzyme, enzyme section cracked ends is crossed BamHI that rubber tapping reclaims back (rubber tapping reclaimer operation reference reagent box operation instructions) and the DNA cloning sequence of the GST that encodes and XhoI enzyme and is cut back to close and cut back to close fragment with the XhoI of pBluescriptSKII with the EcoRI enzyme after fragment is connected and be connected.Connect product transformed into escherichia coli DH
5 α, transformant further determines that through order-checking expressed sequence is correct after cutting evaluation through resistance, blue hickie, enzyme.The extraction plasmid cuts back to close small segment through XhoI and EcoRI enzyme, cuts to be connected with XhoI and the EcoRI enzyme of pPIC9 to be built into expression plasmid pPIC9-gst-GKV-4, transformed into escherichia coli DH
5 αAfter amicillin resistance screening transformant.Press method (the Clare JJ of bibliographical information, etc., Gene, 1991,105:205-212) the competent cell of preparation pichia yeast KM71, and the linearizing recombinant plasmid pPIC9-gst-GKV-4 of SacI single endonuclease digestion transformed through electricity import competent cell, the condition that electricity transforms is 1.5KV, 22.5uF.In the YPD flat board, 30 ℃ of cultivations are screened the positive colony of expressed fusion protein two days later with electric transformed yeast cells coated plate.
Transformant is expressed the GST-GKV-4 fusion rotein through methanol induction.Fusion rotein with the GST affinity column purifying after obtain antibacterial peptide GKV-4, concrete operations reference reagent box operation instructions after the zymoplasm cutting.
GST-GKV-4 fusion rotein sequence:
Leu?Glu?Met?Ser?Pro?Ile?Leu?Gly?Tyr?Trp?Lys?Ile?Lys?Gly?Leu?Val?Gln?Pro?Thr?Arg?Leu?Leu?Leu
Glu?Tyr?Leu?Glu?Glu?Lys?Tyr?Glu?Glu?His?Leu?Tyr?Glu?Arg?Asp?Glu?Gly?Asp?Lys?Trp?Arg?Asn?Lys
Lys?Phe?Glu?Leu?Gly?Leu?Glu?Phe?Pro?Asn?Leu?Pro?Tyr?Tyr?Ile?Asp?Gly?Asp?Val?Lys?Leu?The?Gln
Ser?Met?Ala?Ile?Ile?Arg?Tyr?Ile?Ala?Asp?Lys?His?Asn?Met?Leu?Gly?Gly?Cys?Pro?Lys?Glu?Arg?Ala
Glu?Ile?Ser?Met?Leu?Glu?Gly?Ala?Val?Leu?Asp?Ile?Arg?Tyr?Gly?Val?Ser?Arg?Ile?Ala?Tyr?Ser?Lys
Asp?Phe?Glu?The?Leu?Lys?Val?Asp?Phe?Leu?Ser?Lys?Leu?Pro?Glu?Met?Leu?Lys?Met?Phe?Glu?Asp?Arg
Leu?Cys?His?Lys?The?Tyr?Leu?Asn?Gly?Asp?His?Val?The?His?Pro?Asp?Phe?Met?Leu?Tyr?Asp?Ala?Leu
Asp?Val?Val?Leu?Tyr?Met?Asp?Pro?Met?Cys?Leu?Asp?Ala?Phe?Pro?Lys?Leu?Val?Cys?Phe?Lys?Lys?Arg
Ile?Glu?Ala?Ile?Pro?Gln?Ile?Asp?Lys?Tyr?Leu?Lys?Ser?Ser?Lys?Tyr?Ile?Ala?Trp?Pro?Leu?Gln?Gly
Trp?Gln?Ala?The?Phe?Gly?Gly?Gly?Asp?His?Pro?Pro?Lys?Ser?Asp?Leu?Val?Pro?Arg?Gly?Ser
Lys?Gly?Val?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Cys?Lys?Lys?Leu?Ala?Arg?Lys?Ala?Leu?Lys
GST-GK V-4 nucleotide sequence:
CTCGAGATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGC
AACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGC
ATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTG
AATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTT
AAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACA
ACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTG
AAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAG
TAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAA
ATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGG
TGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTG
TTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGT
TTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATC
CAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGT
GGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTAAAGGTGTTC
GTAAAGGCGCCAAACGCCAGGGTTGCAAGAAACTTGCCCGTAAGGCTT
TGAAGTAGGAATTC
The evaluation of embodiment 4 antibacterial peptides
As shown in Figure 1, the antibacterial peptide GKV-4 of preparation is through mass spectroscopy, and the molecular weight that GKV-4 shows in mass spectrum is 2324.0.The theoretical value that is calculated by peptide sequence is 2324.0.The polypeptide of proof preparation is the GKV-4 antibacterial peptide of design.The antibacterial peptide product of accreditation is standby.
Antibacterial peptide GKV-1, GKV-2 and other antibacterial peptide disclosed by the invention, natural antibacterial peptide GramicidinS, parasinI and magaininII can adopt preparation method's preparation of GKV-4 antibacterial peptide.
The fungicidal activity of embodiment 5 antibacterial peptides detects
Employed various bacterial strains are purchased in Chinese biological goods calibrating institute in following examples.
Adopt 96 well plate method that the fungicidal activity of antibacterial peptide is detected, and with mechanochemical method synthetic antibacterial peptide GramicidinS (S), parasinI (I) and magaininII (II) are in contrast, and with 12 antibacterial peptide GKV-1 among the synthetic the present invention of solid state chemistry synthesis method to GKV-12, detect their fungicidal activity.
Measure the fungicidal activity of antibacterial peptide according to the following steps:
The bacterial classification recovery, the 37 ℃ of overnight incubation in inoculation inclined-plane are chosen bacterium in common LB substratum, 37 ℃ of overnight incubation, it is 10 that dilution bacterium liquid makes bacteria concentration
4-10
5CFU/ml is inoculated in 96 orifice plates by every hole 100ul bacterium liquid, after polypeptide is diluted with certain proportion, adds 10ul in every hole, and 96 orifice plates are placed 37 ℃ of overnight incubation, and microplate reader detects OD
620Value (In Yup Park etc; FEBS Letters; 437 (1998) 258-262).Detected result sees Table 1.
Growth concentration (the OD that contains the bacterium of antibacterial peptide
620) be minimal inhibitory concentration (minimal inhibitory concentration (MIC) is defined as the minimum concentration of remarkable bacteria growing inhibiting) with the ratio of the growth concentration of the bacterium that does not add antibacterial peptide greater than 90% o'clock antibacterial peptide concentration.
Several antibacterial peptides of table 1 are to the comparison of the anti-microbial activity minimal inhibitory concentration (ug/ml) of different bacterium
In the last table the minimal inhibitory concentration value more little, then represent antibacterial ability strong more, as can be seen from the above table, the MIC of antibacterial peptide of the present invention compares GramicidinS, parasinI and magaininII are all little, particularly to the effect of Gram-negative bacteria, the antibacterial ability of antibacterial peptide of the present invention is better than correlated three antibacterial peptides greatly.
The fungicidal activity of embodiment 6 antibacterial peptide function equivalents---cyclisation derivative detects
Design synthetic antibacterial peptide function equivalent: cyclisation GK-20 derivative, synthetic method are seen u.s.a. applied biosystem company (Applied Biosystems) pioneer Peptide synthesizer operational guidance.After the synthetic product process separation and purification (with embodiment 1), detected the minimal inhibitory concentration of derivative, fungicidal activity detects with embodiment 4, and detected result sees Table 2.The sequence of cyclisation GKV-2 derivative is as follows:
GKV-2：
Table 2 antibacterial peptide GKV-2 function equivalent is to the minimal inhibitory concentration (MIC) of different bacterium
Embodiment 3 external hemolytic activities detect
Present embodiment is used to detect antibacterial peptide whether human erythrocyte is had hemolytic activity, and with mechanochemical method synthetic antibacterial peptide GramicidinS, parasinI and magaininII are in contrast.Use blood sample be taken at normal human blood.
The detection step of antibacterial peptide hemolytic activity is:
The release of fresh red blood cell suspension oxyphorase under 414nm of 4% detects.HRBC is through PBS (PBS:35mM phosphoric acid buffer/0.15MNaCl, PH7.0) washing, the 8% HRBC suspension of getting 100ul is in 96 orifice plates, add 100ul antibacterial peptide solution in every hole, 37 ℃ after one hour, centrifugal 5 minutes of 1500rpm shifts the 100ul supernatant in 96 new orifice plates, by the absorption under the microplate reader detection 414nm.Negative control PBS, positive control 0.1%TritonX-100.Detected result sees Table 2
Five kinds of antibacterial peptide hemolytic activities of table 3 detected result
The hemolysis rate value of antibacterial peptide is more little in the table 2, then represents the hemolytic toxicity of antibacterial peptide more little.
Acute toxicity test in embodiment 7 animal bodies
Present embodiment is in order to detecting the toxicity of antibacterial peptide to animal, and with mechanochemical method synthetic antibacterial peptide GramicidinS, parasinI and magaininII measure antibacterial peptide GKV-1 provided by the invention, the toxicity of GKV-2 and GKV-4 in contrast.
Adopt 60 of Kunming small white mouses, male and female half and half, body weight 33.5 ± 0.25g, antibacterial peptide press 1mg/kg dosage, observe animal toxic reaction under maximal dose through the intramuscular injection small white mouse in continuous once a day 7 days.Experimental result shows that animal via intramuscular injection antibacterial peptide is after 7 days, and no abnormal reaction, activity are normally.Observed through 7 days, 60 small white mouses all survive.Proof antibacterial peptide free of toxic effects.
Embodiment 8 antibacterial peptides and vancomycin suppress the comparison of effect to mouse infection of staphylococcus aureus model
Use the streptococcus aureus acute infection model of Kunming small white mouse, experimental procedure is as follows:
Place the veal that contains 5% pig gastric mucoitin to inculcate in the meat soup streptococcus aureus CMCC26003, shaking culture is spent the night.Injection 10 in the mouse peritoneal of the about 32.6 ± 0.25g of body weight
6-10
7Survivaling cell has 3 mouse in each treatment group.Intravenous injection antibacterial peptide GKV-1 and GKV-3 (being dissolved in respectively in 0.1 milliliter of 5% dextrose) for injection, injection in 10 minutes.The subcutaneous injection vancomycin (but vancomycin is complete biological utilisation to the mouse subcutaneous administration, no matter subcutaneous give or vein has similar activity).
Table 4 antibacterial peptide GKV-1, GKV-3 and vancomycin are to the restraining effect of streptococcus aureus acute infection small white mouse model
As shown in table 3, intravenous injection gives 0.25mg/kg, antibiotic Toplink 100% protection infecting mouse.Vancomycin is just 100% effective under 4.0 milligrams/kg dosage.All untreated mice are all dead in less than 24 hours.
This experimental example shows that antibacterial peptide is highly effective to killing streptococcus aureus with the chmice acute infection model of the fatal bacterium dosage of height.
Sequence table
＜110〉Shanghai Hi-Tech United Biotechnology R ﹠ D Ltd
＜120〉one group of new antibacterial peptide and its production and application
<130>
<160>12
<170>Patent?In?Version2.1
<210>1
<211>25
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>1
Lys?Gly?Ala?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Val
5 10 15
Ala?Arg?Lys?Ala?Leu?Lys?Arg?Ala?Gly?Lys
20 25
<210>2
<211>25
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>2
Lys?Gly?Gly?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Leu
5 10 15
Ala?Arg?Lys?Ala?Leu?Lys?Arg?Ala?Gly?Arg
20 25
<210>3
<211>21
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>3
Lys?Gly?Gly?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Gly?Lys?Lys?Leu
5 10 15
Ala?Arg?Lys?Ala?Leu?Lys
20
<210>4
<211>21
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>4
Lys?Gly?Val?Arg?Lys?Gly?Ala?Lys?Arg?Gln?Gly?Cys?Lys?Lys?Leu
5 10 15
Ala?Arg?Lys?Ala?Leu?Lys
20
<210>5
<211>20
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>5
Lys?Gly?Ala?Arg?Arg?Gly?Ala?Lys?Arg?Gly?Gly?Lys?Lys?Leu?Ala
5 10 15
Arg?Lys?Ala?Leu?Lys
20
<210>6
<211>20
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>6
Lys?Gly?Ala?Arg?Arg?Leu?Ala?Lys?Arg?Ser?Gly?Lys?Lys?Val?Ala
5 10 15
Arg?Lys?Ala?Gly?Arg
20
<210>7
<211>20
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>7
Lys?Phe?Ala?Arg?Arg?Leu?Ala?Lys?Arg?Leu?Gly?Lys?Lys?Val?Ala
5 10 15
Arg?Lys?Leu?Gly?Arg
20
<210>8
<211>20
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>8
Lys?Phe?Leu?Arg?Arg?Leu?Ile?Lys?Arg?Leu?Val?Lys?Lys?Val?Leu
5 10 15
Arg?Lys?Leu?Gly?Arg
20
<210>9
<211>16
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>9
Lys?Ala?Ala?Lys?Lys?Ala?Ala?Lys?Arg?Ala?Ala?Lys?Lys?Ala?Thr
5 10 15
Arg
<210>10
<211>16
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>10
Lys?Ala?Leu?Lys?Lys?Ala?Leu?Lys?Arg?Ala?Leu?Lys?Lys?Ala?Leu
5 10 15
Arg
<210>11
<211>16
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>11
Lys?Gly?Leu?Lys?Lys?Gly?Leu?Lys?Arg?Gly?Leu?Lys?Lys?Gly?Leu
5 10 15
Arg
<210>12
<211>16
<212>PRT
＜213〉artificial sequence
<220>
<221>CHAIN
<400>12
Lys?Ala?Thr?Lys?Lys?Ala?Leu?Lys?Arg?Ala?Gly?Lys?Lys?Ala?Thr
5 10 15
Arg
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102234099A CN101781358B (en) | 2004-11-16 | 2004-11-16 | Novel antibacterial peptide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102234099A CN101781358B (en) | 2004-11-16 | 2004-11-16 | Novel antibacterial peptide and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410068195 Division CN1634981B (en) | 2004-11-16 | 2004-11-16 | A group of new antimicrobial peptides and their preparation methods and applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101781358A true CN101781358A (en) | 2010-07-21 |
| CN101781358B CN101781358B (en) | 2012-08-08 |
Family
ID=42521520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102234099A Expired - Fee Related CN101781358B (en) | 2004-11-16 | 2004-11-16 | Novel antibacterial peptide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101781358B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106632606A (en) * | 2016-12-26 | 2017-05-10 | 中国农业大学 | Antimicrobial lipopeptide bacaucin derivatives and application thereof in bacterial infection inhibition |
| WO2018086516A1 (en) * | 2016-11-09 | 2018-05-17 | 湖南科技学院 | Antibacterial peptide of inhibiting drug-resistant bacteria and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998489B1 (en) * | 1998-03-25 | 2003-06-18 | Korea Advanced Institute of Science and Technology | A NOVEL ANTIMICROBIAL PEPTIDE ISOLATED FROM $i(PARASILURUS ASOTUS) AND ITS USES |
-
2004
- 2004-11-16 CN CN2009102234099A patent/CN101781358B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018086516A1 (en) * | 2016-11-09 | 2018-05-17 | 湖南科技学院 | Antibacterial peptide of inhibiting drug-resistant bacteria and application thereof |
| US10603350B2 (en) | 2016-11-09 | 2020-03-31 | Hunan University Of Science And Engineering | Antimicobial peptides for inhibiting drug-resistant bacteria and uses thereof |
| CN106632606A (en) * | 2016-12-26 | 2017-05-10 | 中国农业大学 | Antimicrobial lipopeptide bacaucin derivatives and application thereof in bacterial infection inhibition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101781358B (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101570569B (en) | Synthetic antibacterial peptide and preparation method and application thereof | |
| CN101155825B (en) | Antimicrobial hexapeptides | |
| Conlon et al. | Isolation of peptides of the brevinin‐1 family with potent candidacidal activity from the skin secretions of the frog Rana boylii | |
| Savelyeva et al. | An overview of Brevinin superfamily: structure, function and clinical perspectives | |
| CN102219831B (en) | Antibiotic peptide as well as preparation method and application thereof | |
| CN101284876B (en) | Fusion protein Penharpin and its preparation method and use | |
| CN101801995A (en) | antibiotic peptides | |
| CN102369210A (en) | Antibiotic peptides | |
| CN101215325B (en) | Antibiotic peptides, preparation method and application thereof | |
| Machado et al. | Synthesis and properties of cyclic gomesin and analogues | |
| US7629438B2 (en) | Group of synthetic antimicrobial peptides | |
| US8663916B2 (en) | Methods for producing antifungal bifunctional molecules for treating fungal infection | |
| CN100365018C (en) | Antibiotic peptides and their prepn process and application | |
| Conlon et al. | Peptide defenses of the Cascades frog Rana cascadae: implications for the evolutionary history of frogs of the Amerana species group | |
| CN101182351A (en) | Antibiotic peptide as well as preparation method and application thereof | |
| JPH07501820A (en) | Compositions and treatments with bioactive peptides and chelating agents | |
| CN101781359B (en) | Novel antibacterial peptide and preparation method and application thereof | |
| CN1634981B (en) | A group of new antimicrobial peptides and their preparation methods and applications | |
| CN102391370B (en) | Antimicrobial peptides, preparation method and application thereof | |
| CN101781358A (en) | Novel antibacterial peptide and preparation method and application thereof | |
| CN118638188A (en) | Database-assisted design of antimicrobial peptides targeting Escherichia coli and preparation method and application thereof | |
| CN102391364A (en) | New antibacterial peptides as well as preparation method and application of the same | |
| CN102391365A (en) | A group of new antibiotic peptides, preparation method thereof and use thereof | |
| CN113527513B (en) | Preparation method and application of hybrid antibacterial peptide Spcrus-APP | |
| CN103204910A (en) | Cyclized peptide and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GAOKE UNION BIOTECHNOLOGY DEVELOPMENT CO. Effective date: 20131205 Owner name: GAOKE BIO-ENGINEERING CO LTD, SHANGHAI Free format text: FORMER OWNER: SHANGHAI GAOKE UNION BIOTECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20131205 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131205 Address after: 201206 B building, No. 501 Jingang Road, Jinqiao Development Zone, Shanghai, Pudong New Area, 5 Patentee after: Shanghai Hi-tech Bioengineering Ltd. Patentee after: Shanghai Hi-Tech United Bio-Technological Research & Development Co.,Ltd. Patentee after: KUNSHAN BIOGREEN TECHNOLOGY Co.,Ltd. Address before: 201206, No. 3, building B, block 501, Jingang Road, Shanghai, Pudong New Area Patentee before: Shanghai Hi-Tech United Bio-Technological Research & Development Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GAOKE UNION BIOTECHNOLOGY DEVELOPMENT CO. Free format text: FORMER OWNER: SHANGHAI GAOKE UNION BIOTECHNOLOGY DEVELOPMENT CO., LTD. KUNSHAN BOQING BIO-TECHNOLOGY CO., LTD. Effective date: 20150521 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150521 Address after: 201206 B building, No. 501 Jingang Road, new Jinqiao Development Zone, Shanghai, Pudong New Area, 5 Patentee after: Shanghai Hi-tech Bioengineering Ltd. Patentee after: Shanghai Hi-Tech United Bio-Technological Research & Development Co.,Ltd. Address before: 201206 B building, No. 501 Jingang Road, Jinqiao Development Zone, Shanghai, Pudong New Area, 5 Patentee before: Shanghai Hi-tech Bioengineering Ltd. Patentee before: Shanghai Hi-Tech United Bio-Technological Research & Development Co.,Ltd. Patentee before: KUNSHAN BIOGREEN TECHNOLOGY Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |